The FDA approved a supplemental application for Opdivo (nivolumab) on June 10, 2020. This approval, submitted by Bristol Myers Squibb, specifically pertains to the drug's efficacy.
What this means
A supplemental approval for efficacy, such as this one for Opdivo (nivolumab), indicates that the FDA has reviewed and accepted new clinical data demonstrating the drug's effectiveness for an expanded or modified use. While the specific details regarding the new indication, patient population, or revised treatment guidelines are not provided in the available data, this type of regulatory action typically allows clinicians to utilize Opdivo (nivolumab) in additional contexts where its efficacy has been scientifically validated. This can lead to expanded treatment options for patients and a more comprehensive understanding of the drug's overall utility in clinical practice, reinforcing its established role as a therapeutic agent.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-81, concerning Opdivo (nivolumab), was recorded on June 10, 2020, on accessdata.fda.gov.